Drugs /

leuprolide

Back to Drugs List
Associated Genetic Biomarkers
Associated Diseases

Overview

Generic Name(s):
leuprolide
Trade Name(s):
Lupron, Prostap, Viadur, Leuplin, Enantone, Procren, Depo-Eligard, Lupron Depot-Ped, Ginecrin, Trenantone, Enanton, Uno-Enantone, Lupron Depot-3 Month, Carcinil, Lupron Depot-4 Month, Lucrin, Lucrin Depot, Lupron Depot, Enantone-Gyn, and Procrin
NCI Definition [1]:
A synthetic nonapeptide analogue of gonadotropin-releasing hormone. Leuprolide binds to and activates gonadotropin-releasing hormone (GnRH) receptors. Continuous, prolonged administration of leuprolide in males results in pituitary GnRH receptor desensitization and inhibition of pituitary secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. This agent reduces testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression.

Biomarker-Directed Therapies

Clinical Trials

View Clinical Trials for leuprolide

Leuprolide has been investigated in 30 clinical trials, of which 24 are open and 6 are closed. Of the trials investigating leuprolide, 2 are phase 1/phase 2 (2 open), 20 are phase 2 (14 open), 7 are phase 3 (7 open), and 1 is no phase specified (1 open).

ER Expression, ER Positive, and PR Expression are the most frequent biomarker inclusion criteria for leuprolide clinical trials.

Prostate adenocarcinoma, breast carcinoma, and prostate carcinoma are the most common diseases being investigated in leuprolide clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Leuprolide
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Leuprolide
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating leuprolide and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Viadur, Carcinil, Depo-Eligard, leuprorelinum, l-pyroglutamyl-l-histidyl-l-tryptophyl-l-seryl-l-tyrosyl-d-leucyl-l-leucyl-l-arginyl-l-proline ethylamide, leuprorelin (substance), (d-leu(6),des-gly-nh2(10),pro-ethylamide(9))-gonadotropin-releasing hormone, 6-d-leucine-9-(n-ethyl-l-prolinamide)-10-deglycinamide luteinizing hormone-releasing factor (pig), tol2506, Enanton, Enantone, Enantone-Gyn, Ginecrin, Leuplin, Lucrin, Lucrin Depot, Procren, Procrin, Prostap, Trenantone, Uno-Enantone, leuprolide (product), leuprorelina, pglu-his-trp-ser-tyr-d-leu-leu-arg-pro-nhet, luteinizing hormone-releasing factor (pig), 6-d-leucine-9-(n-ethyl-l-prolinamide)-10-deglycinamide-, leuproreline, leuprolide [chemical/ingredient], pglu-his-trp-ser-tyr-d-leu-leu-arg-pro-nhc2h5, leuprolide, leuprorelin, leuprolide, 6-d-leucine-9-(n-ethyl-l-prolinamide)-1-9-luteinizing hormone-releasing factor (pig)
Drug Target(s) [2]:
GNRHR
NCIT ID [1]:
C62042
SNOMED ID [1]:
F-B1083

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.